Lipocine announces initiation of outpatient phase 3 postpartum depression trial of lpcn 1154

48 hour at-home dosing patient dosing expected in q2/2025 salt lake city , march 26, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a phase 3 trial for lpcn 1154 (oral brexanolone) which is in development for the treatment of postpartum depression (ppd).   based on observed comparable exposure of lpcn 1154 and the reference drug established in the pharmacokinetic (pk) bridge study, the company is initiating a phase 3 safety and efficacy study with expected first patient dosed in the second quarter of 2025.
LPCN Ratings Summary
LPCN Quant Ranking